Positive vote for Lorqess (and Qnexa) is no guarantee of obe$ity $uccess
This article was originally published in Scrip
Executive Summary
Arena's Lorqess (lorcaserin) has moved one step closer to approval for the treatment of obesity following a positive review by the FDA advisory committee. The result came as a surprise to some, after the drug was rejected in 2010 due to safety concerns. Despite the good news for Arena Pharmaceuticals, the drug's commercial prospects remain uncertain: the path to launch is unclear, and uptake may be slow.